DDIT4 and plasma cell myeloma: Concerning markers mimicking GC-related side effects, we have shown that REDD1 (DDIT4), an instigator of myeloma cell growth and survival [50], is decreased by Dex-Spi combination compared to Dex in MM1.S and OPM-2 (Fig. 6D).